CureVac N.V. (NASDAQ:CVAC) Given Average Recommendation of “Hold” by Brokerages

Shares of CureVac N.V. (NASDAQ:CVAC) have earned a consensus recommendation of “Hold” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $6.8333.

Separately, Weiss Ratings reiterated a “hold (c-)” rating on shares of CureVac in a report on Wednesday, October 8th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd raised its holdings in CureVac by 354.8% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 5,608 shares of the company’s stock worth $30,000 after acquiring an additional 4,375 shares during the period. Greenleaf Trust bought a new position in CureVac in the 1st quarter worth $31,000. Headlands Technologies LLC bought a new position in CureVac in the 2nd quarter worth $35,000. Integrated Wealth Concepts LLC raised its holdings in CureVac by 25.0% in the 1st quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company’s stock worth $42,000 after acquiring an additional 3,000 shares during the period. Finally, Kathmere Capital Management LLC bought a new position in shares of CureVac during the 2nd quarter worth about $60,000. Institutional investors own 17.26% of the company’s stock.

CureVac Stock Down 0.4%

CureVac stock opened at $5.34 on Tuesday. The company has a market capitalization of $1.20 billion, a P/E ratio of 5.56 and a beta of 2.51. The firm’s fifty day simple moving average is $5.38 and its 200-day simple moving average is $4.95. The company has a current ratio of 6.17, a quick ratio of 6.16 and a debt-to-equity ratio of 0.05. CureVac has a 1-year low of $2.37 and a 1-year high of $5.72.

CureVac (NASDAQ:CVAC) last released its quarterly earnings results on Thursday, August 21st. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.15). The business had revenue of $1.41 million for the quarter, compared to the consensus estimate of $4.27 million. CureVac had a net margin of 38.21% and a return on equity of 29.57%. Sell-side analysts forecast that CureVac will post 0.72 earnings per share for the current fiscal year.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.